Central Nervous System
PV QA 2 - Poster Viewing Q&A 2
MO_11_2729 - Genomic Copy Number Gains of ErbB Family Members Predict Poor Clinical Outcomes in Glioma Patients
Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3
Genomic Copy Number Gains of ErbB Family Members Predict Poor Clinical Outcomes in Glioma Patients
L. Rui, Q. yi Ping, H. Peng, and C. li Hong; The First Affiliated Hospital of Xi’an Jiaotong University, xi'an, China
Purpose/Objective(s): The aim of this study was to investigate copy number of ErbB family members (including EGFR, HER2, HER3 and HER4) in a cohort of gliomas and benign meningiomas (control subjects), and explore the associations of their copy number with clinicopathological characteristics and clinical outcomes of glioma patients.
Materials/Methods: a total of 127 glioma patients and 16 benign meningiomas as control subjects, who underwent surgery for brain tumors at the Department of Neurosurgery of First Affiliated Hospital of Xi’an Jiaotong University from 2006 to 2012, were randomly enrolled in this study (Supplementary Table 1). None of these patients receive radiotherapy or chemotherapy prior to surgery. Glioma patients received adjuvant radiotherapy and/or chemotherapy after surgery according to standard clinical protocols. All samples were histopathologically classified according to the WHO classification criteria. Overall survival was calculated as time duration starting from surgery until cancer-related death or last follow-up. Using real-time quantitative PCR assay, we analyzed that copy number of EGFR, HER2, HER3 and HER4 in glioma patients and benign meningiomas.
Results: The copy number of EGFR, HER2, HER3 and HER4 in glioma patients was significantly increased compared to control subjects. Moreover, our data also showed that the risk of cancer-related death was positively associated with copy number gain (CNG) of EGFR, HER3 and HER4, but not HER2. CNG of EGFR and HER2 was positively related to radiotherapy, while CNG of HER3 and HER4 was negatively related to chemotherapy. Importantly, EGFR CNG significantly shortened median survival times of glioma patients regardless of gender, tumor grade and therapeutic regimens. Stratified analysis showed that CNG of HER2-4 almost did not influence the survival of male patients, the patients with high-grade tumors and the patients receiving chemotherapy, but dramatically shortened median survival times of female patients, those with low-grade tumors and those receiving radiotherapy.
Conclusion: Collectively, our data not only demonstrate that the members of ErbB family are frequently amplified in gliomas, but also suggest that these common genetic events may be prognostic factors for poor clinical outcomes in glioma patients.
Author Disclosure: L. Rui: None. Q. yi Ping: None. H. Peng: None.